- Home
- URGN
URGN
UroGen Pharma Ltd.
as of 03-03-2026 10:08am EST
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RA'ANANA |
| Market Cap: | 922.1M | IPO Year: | 2016 |
| Target Price: | $29.29 | AVG Volume (30 days): | 697.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.19 | EPS Growth: | -7.77 |
| 52 Week Low/High: | $3.42 - $30.00 | Next Earning Date: | 06-10-2026 |
| Revenue: | $1,128,000 | Revenue Growth: | -86.17% |
| Revenue Growth (this year): | 119.37% | Revenue Growth (next year): | 64.79% |
| P/E Ratio: | -5.98 | Index: | N/A |
| Free Cash Flow: | -162733000.0 | FCF Growth: | N/A |
AI-Powered URGN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of UroGen Pharma Ltd. (URGN)
General Counsel
Avg Cost/Share
$19.69
Shares
7,479
Total Value
$147,261.51
Owned After
52,934
Chief Medical Officer
Avg Cost/Share
$19.69
Shares
7,373
Total Value
$145,174.37
Owned After
150,514
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Smith Jason Drew | URGN | General Counsel | Feb 3, 2026 | Sell | $19.69 | 7,479 | $147,261.51 | 52,934 | |
| Schoenberg Mark | URGN | Chief Medical Officer | Feb 3, 2026 | Sell | $19.69 | 7,373 | $145,174.37 | 150,514 |
Compare URGN vs Leading Stocks
See how URGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "URGN UroGen Pharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.